What are the recommended stereotactic body radiotherapy (SBRT) dose regimens and indications for early‑stage non‑small cell lung cancer?

SBRT for Early-Stage Non-Small Cell Lung Cancer

For medically inoperable patients with stage I NSCLC, stereotactic body radiotherapy (SBRT/SABR) is the definitive non-surgical treatment of choice, delivered to a biologically equivalent tumor dose (BED10) of ≥100 Gy prescribed to the encompassing isodose. 1, 2, 1

Primary Indications

SBRT should be offered to:

• Medically inoperable patients with clinical stage I (T1-2N0M0) NSCLC as the standard curative treatment 1, 2, 3
• Operable patients who refuse surgery after thoracic surgical evaluation, though surgery remains the standard of care for medically fit patients 3, 4
• Patients with COPD and elderly patients with early-stage peripheral lung tumors, where SBRT demonstrates low toxicity 1, 2, 1

Dose Regimens

The optimal BED10 is ≥100 Gy, with evidence suggesting superior outcomes at ≥130 Gy: 3, 5

For Peripheral Tumors (outer one-third of lung):

• 54-60 Gy in 3 fractions (BED10 ~150-180 Gy) - associated with lowest local failure rate of 4.3% at 2 years 6
• 48-50 Gy in 4-5 fractions (BED10 ~106-132 Gy) 6
• 30-34 Gy in 1 fraction - higher local failure rate of 21% at 2 years, less preferred 6

For Central Tumors (within 2 cm of mediastinal structures):

• 50 Gy in 5 fractions 7, 6
• 60 Gy in 8 fractions 6
• 50 Gy in 10 fractions 6

Risk-adapted fractionation schedules are mandatory for central tumors to reduce toxicity to critical structures including bronchial tree, esophagus, heart, major vessels, and spinal cord. 7, 8

Tumor Size and Location Considerations

For tumors >5 cm and/or central location:

• Conventional radical radiotherapy using more conventional or accelerated schedules is recommended over standard SBRT 1
• Central tumors require dose reduction per fraction or increased number of fractions 8

Ultracentral tumors (planning target volume overlapping trachea or main bronchi) should not receive standard SBRT due to increased toxicity risk. 7

Evidence Quality and Comparative Outcomes

The highest quality evidence comes from a pooled analysis of randomized trials (STARS and ROSEL) showing:

• 3-year overall survival: 95% with SBRT vs 79% with surgery (P = 0.037) 8
• However, these trials closed early due to poor accrual, and surgery remains standard for operable patients 7, 3, 4

National database analysis (25,039 patients) demonstrates:

• BED10 ≥130 Gy associated with better 5-year overall survival (34%) compared to BED10 100-129 Gy (26%) 5
• This supports using higher BED regimens when safely achievable 5

Toxicity Profile

SBRT demonstrates favorable toxicity compared to surgery: 3, 8

• Grade 3-4 toxicity: 10-30% 9
• Higher dose regimens (54-60 Gy in 3 fractions) show slightly increased toxicity:
  • Pulmonary toxicity: 5.0% vs 3.2-3.8% for other regimens 6
  • Chest wall toxicity: 23.7% vs 7.7-8.6% for other regimens 6

Critical advantage: No general anesthesia required, minimal recovery time, preserved lung function 8

Important Limitations

Clinicians must counsel patients about SBRT's inherent limitations:

• No systematic nodal sampling - relies on radiographic staging only, risking under-staging of occult nodal disease 8
• Limited tissue for molecular profiling - only bronchoscopic or needle biopsy available 8
• Risk of treating benign lesions without histologic confirmation 8
• Distant failure occurs in up to 33% of patients at 3 years 9

Salvage Options

Salvage surgery may be offered post-SBRT for:

• Complications after SBRT 1, 7
• Progressive disease using same indications as primary surgery, though operative risk is higher 1, 7

Follow-Up Protocol

Surveillance schedule: 1

• Every 6 months for 2-3 years with history, physical examination, and contrast-enhanced spiral chest CT at 12 and 24 months
• Annual visits thereafter with chest CT to detect second primary tumors
• PET-CT surveillance not routinely recommended 1
• For centers newly implementing SABR: 6-monthly CT scans for 3 years to benchmark outcomes 1

Common Pitfalls to Avoid

• Do not use SBRT for ultracentral tumors with standard dosing - use hypofractionated conventional RT instead 7
• Do not use BED10 <100 Gy - associated with inferior local control 3, 5
• Do not offer SBRT to operable standard-risk patients as routine alternative to surgery outside clinical trials 3, 4
• Do not skip tissue diagnosis when feasible - needed for molecular profiling and to exclude benign disease 8